Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960701 | 0.80 | CYP1A2 (0.36) | ATMCYP1A2TSHRPOLBEDNRB | |
| SCHEMBL9960657 | 0.75 | MEN1 (0.42) | L3MBTL1CYP1A2TSHRPOLBKMT2A | |
| SCHEMBL9960819 | 0.72 | LMNA (0.36) | ATML3MBTL1CYP1A2TSHRALDH1A1 | |
| SCHEMBL9960857 | 0.72 | ALDH1A1 (0.39) | CYP1A2TSHRALDH1A1POLBHSD17B10 | |
| SCHEMBL9960707 | 0.70 | ALDH1A1 (0.35) | CYP1A2TSHRALDH1A1POLBHBB | |
| SCHEMBL17357501 | 0.67 | L3MBTL1 (0.61) | ATML3MBTL1KMT2APTGS2 | |
| SCHEMBL66018 | 0.67 | L3MBTL1 (0.61) | ATML3MBTL1KMT2APTGS2 | |
| SCHEMBL9960728 | 0.66 | PKM (0.33) | CYP1A2TSHRALDH1A1POLBHBB | |
| SCHEMBL9960856 | 0.66 | PKM (0.33) | CYP1A2TSHRALDH1A1POLBHBB | |
| SCHEMBL9960826 | 0.64 | LTB4R (0.36) | CYP1A2TSHRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | claimed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | claimed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | ATM 3599/4885L3MBTL1 2548/4885CYP1A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.